EWTX is evaluating EDG-7500 in the ongoing phase II CIRRUS-HCM study. In patients with obstructive HCM, Edgewise Therapeutics reported that treatment with EDG-7500 demonstrated meaningful ...

EWTX is evaluating EDG-7500 in the ongoing phase II CIRRUS-HCM study. In patients with obstructive HCM, Edgewise Therapeutics reported that treatment with EDG-7500 demonstrated meaningful ...

It was a busy week for the biotech sector, with lots of regulatory and pipeline updates amid fears of a global recession ...

Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb are included in this Analyst Blog.

It was a busy week for the biotech sector, with lots of regulatory and pipeline updates amid fears of a global recession sparked by the ongoing global trade war. Most bigwigs came out with ...

We recently published a list of 20 Stocks Insiders Bought in April After Trump’s Tariff Rollout. In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands ...

Kevin Koch, the President and CEO of Edgewise Therapeutics , Inc. (NASDAQ:EWTX), recently sold shares in the company valued at ...

Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to ...

HCM Tactical Growth Fund earns an Above Average Process Pillar rating. The predominant contributor to the rating is the fund's impressive long-term risk-adjusted performance. This can be seen in ...